Mr Stephen Gamble University positionResearch Assistant (retired) InstitutesWellcome Trust Sanger Institute Home pagehttp://www.sanger.ac.uk/science... Research ThemeInterestsI have recently retired from the Cancer, Ageing and Somatic Mutation (CASM) team at the Sanger Institute. Previously I have worked for the MRC on the biological basis of mental illness using neurobiology, biochemistry and computing. I am also interested in the analysis of sequential behaviour.
Being retired has given me more time to follow my own areas of interest. I am particularly interested in the roles of mitochondria, genetics and autoimmunity in cancers and neurological disease,
Research Focus
EquipmentNo equipment indicated CollaboratorsNo collaborators listed Associated News ItemsPublications1989Annett LE, Ridley RM, Gamble SJ, Baker HF (1989), “Social withdrawal following amphetamine administration to marmosets.” Psychopharmacology (Berl) 99(2):222-9 Details 1985Taylor GR, Crow TJ, Carter GI, Gamble SJ (1985), “Cytopathogenic cerebrospinal fluid from neurological and psychiatric patients.” Exp Mol Pathol 42(2):271-7 Details Taylor GR, Roberts GW, Crow TJ, Royds JA, Gamble SJ, Taylor CB, Carter GI, Timperley WR (1985), “The cytopathogenic agent in CSF: evidence for a relationship with enolase levels.” J Neurol Neurosurg Psychiatry 48(3):281 Details 1983Annett LE, Ridley RM, Gamble SJ, Baker HF (1983), “Behavioural effects of intracerebral amphetamine in the marmoset.” Psychopharmacology (Berl) 81(1):18-23 Details Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ (1983), “Adverse effects of anticholinergic medication on positive schizophrenic symptoms.” Psychol Med 13(3):513-27 Details Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983), “Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.” Science 220(4596):530-2 Details Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983), “Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.” Adv Biochem Psychopharmacol 37:299-308 Details 1981Waddington JL, Gamble SJ (1981), “Prolonged dopamine receptor blockade in rats after termination of long-term depot fluphenazine.” Lancet 1(8234):1375-6 Details Waddington JL, Gamble SJ, Bourne RC (1981), “Sequelae of 6 months continuous administration of cis(Z)-and trans(E)-flupenthixol in the rat.” Eur J Pharmacol 69(4):511-3 Details 1980Owen F, Cross AJ, Waddington JL, Poulter M, Gamble SJ, Crow TJ (1980), “Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration.” Life Sci 26(1):55-9 Details Waddington JL, Gamble SJ (1980), “Emergence of apomorphine-induced 'vacuous chewing' during 6 months continuous treatment with fluphenazine decanoate.” Eur J Pharmacol 68(3):387-8 Details Waddington JL, Gamble SJ (1980), “Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.” Eur J Pharmacol 67(4):363-9 Details Waddington JL, Gamble SJ (1980), “Differential effects of ageing on distinct features of apomorphine stereotypy in the adult rat.” Neurosci Lett 20(1):95-9 Details Waddington JL, Gamble SJ (1980), “Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.” Psychopharmacology (Berl) 71(1):75-7 Details |